Most cancer immunotherapies primarily rely on T cells to neutralize tumors. But in two new studies, scientists at Dana-Farber Cancer Institute and Stanford University have described novel immuno-oncology approaches, showing that leveraging other components of the immune system may achieve better antitumor effects.
In a Nature study, a team led by Dana-Farber developed a cancer vaccine that targeted both T cells and natural killer (NK) cells in a two-pronged attack to prevent tumor cells from evading an immune attack.
